Lilly’s Zyprexa is leading the bipolar market in terms of revenue and life cycle management, with recent approval for reformulation in a combination pill with Prozac as Symbyax
February 29, 2004--The bipolar disorder market is experiencing a renewed expansion in product life-cycle
management. Presently, mood stabilizers are the basis of treatment, although the antipsychotics led by Zyprexa, are evolving as a new therapeutic strategy. Companies will have to differentiate their products in the increasingly crowded market if they wish to protect their market share.
This report is designed to show:
Analysis is based on a survey of 164 treating physicians in the seven major markets as well as in-depth interviews with Bipolar key opinion leaders
Detailed treatment trees showing the prevalence, diagnosis and treatment rates of bipolar across the seven major markets
Assessment of the use of mono- and combination-therapy in specific bipolar affective episodes
Identification of therapeutic and diagnostic unmet needs, highlights areas where stakeholder investment is vital to drive patient identification
The report is also designed to highlights:
The primary research has identified variances in class and brand prescribing preferences among physicians, according to BD type and geography; although prescribing trends generally follow recognized national and international guidelines. However, there is concern over the use of tricyclic antidepressants in bipolar depression.
Only 48% of the BD population are accurately diagnosed. We have highlighted a number of serious diagnostic issues, which infers that many of the patients currently diagnosed may receive incorrect BD categorization.
Lilly’s Zyprexa is currently leading the bipolar market in terms of revenue and life cycle management, with recent approval for maintenance therapy and reformulation in a combination pill with Prozac as Symbyax. Other atypical antipsychotics appear to be following suit, and could threaten anticonvulsant dominance of mood stabilization.
Reasons to purchase the report:
Understand differential treatment unmet needs in key patient populations identified by sex, co-morbidities and bipolar disorder type
Gain expert insight into current diagnostic unmet needs and key growth areas in the public and healthcare sectors
Target physicians more effectively, through an understanding of prescribing behavior
Region: US, Japan, France, Germany, Italy, Spain, UK
For a complete index of this report click on
http://www.researchandmarkets.com/reports/45903
About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies,
new products and the latest market trends.
For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com
or mailto:press@researchandmarkets.com
This article courtesy of http://www.zyprexa-side-effects.info.
You may freely reprint this article on your website or in
your newsletter provided this courtesy notice and the author
name and URL remain intact.